Why I Invest in Biotech Stocks

$9.1 billion…

This is the combined value of the treatment market for Alzheimer’s disease and Parkinson’s disease: two diseases that wreaked havoc on my grandmother and great-grandmother.

I’m not going to lie: Watching my loved ones suffer from these horrible diseases was not easy.

And in fact, one of the reasons I’m often investing in the biotech space is because I want to be a part of any potential treatment for any variety of illnesses that still have no cure.

The other reason, of course, is money.

Lots of money.

And that’s why I’m writing to you today. 

$1 Billion up for Grabs

I remember when my grandmother first started suffering from Parkinson’s.

It wasn’t a pleasant time. 

You see, she was an artist.

Her specialty was tropical wildlife scenes.

Let’s just say there are a lot of bird paintings in my home. 🙂 

But when the Parkinson’s started kicking in, she couldn’t paint the way she used to.

She struggled more and more to hold a paintbrush.

Her vision suffered quite a bit, too.

Eventually, her easel sat empty.

It was heartbreaking.

And what was so irritating was that there was nothing we could do. 

So when I recently read about a potential new cure for Parkinson’s, I was floored.

Just think about how many people could have their lives back if such a thing really comes to fruition.

And of course, as an investor, the wheels started turning too when I realized what the value of such a cure could be.

According to the Longevity Fund, a venture capital firm invests specifically in companies that are seeking cures for aging-related diseases, such as Parkinson’s. A single age-related indication could be worth a couple hundred billion dollars. 

That’s billion with a “B.”

Now here’s the best  part …

This potential cure for Parkinson’s is being developed by a public company that you can invest in right now. 

Clinical trials are set to begin shortly, and if this thing proves to be effective, it will be a game-changer of epic proportions.  

Certainly for those suffering from Parkinson’s and other age-related chronic diseases, but also for investors who get an early piece of this action.

You can read more about the science behind this potential cure here.

And to learn more about the company, including its ticker symbol, click here now.

To a new way of life and a new generation of wealth…

Jeff Siegel

Check us out on YouTube!

@JeffSiegel on Twitter

Jeff is an editor of Energy and Capital as well as a contributing analyst for New World Assets.

Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.